Niños con trasplante de progenitores hematopoyéticos admitidos en una unidad de cuidados intensivos: análisis de la sobrevida y los factores predictivos de mortalidad / Children admitted to a pediatric intensive care unit after hematopoietic stem cell transplantation: Analysis of survival and predictors of mortality

Introducción: El trasplante de células progenitoras hematopoyéticas (TPH) en niños es un procedimiento no exento de complicaciones graves. El ingreso de esta población a unidades de cuidados intensivos pediátricos (UCIP) se asocia con elevada mortalidad. Objetivos: Analizar la sobrevida y los factores predictivos de la mortalidad en niños que recibieron TPH e ingresaron a la UCIP y elaborar un modelo predictivo de mortalidad en esta población. Materiales y métodos: Revisión retrospectiva de niños y adolescentes que recibieron un TPH entre el 01/01/2005 y el 31/12/2019 e ingresaron a la UCIP de un hospital universitario de alta complejidad. Resultados: De un total de 264 niños que recibieron el trasplante, 114 ingresaron a la UCIP. La mortalidad general fue del 29 % (n = 34). El tipo de trasplante, enfermedad basal, evento de neutropenia febril, infección por citomegalovirus, insuficiencia respiratoria, enfermedad de injerto contra huésped (EICH), quimioterapia mieloablativa y desnutrición previa se asociaron con tasas de mortalidad más elevadas. En el análisis multivariado, la EICH (razón de posibilidades [OR, por su sigla en inglés]: 2,23; intervalo de confianza del 95 % [IC 95 %]: 1,92-2,98), la necesidad de ventilación mecánica invasiva (OR: 2,47; IC95 %: 1,39-5,73), el trasplante de donante alternativo (OR: 1,58; IC 95 %: 1,14-2,17) y la desnutrición previa (OR: 1,78; IC 95 %: 1,223-3,89) se asociaron con mayor mortalidad. Conclusión: En la población estudiada, dos de cada tres niños que recibieron TPH e ingresaron a la UCIP sobrevivieron. La EICH, ventilación mecánica, trasplante de donante alternativo y desnutrición previa fueron factores predictivos de mortalidad

Introduction: Hematopoietic stem cell transplantation (HSCT) in children is a procedure that is not exempt of severe complications. Admission to the pediatric intensive care unit (PICU) is associated with a high mortality rate. Objectives: To analyze survival and predictors of mortality among children who received a HSCT and were admitted to the PICU, and to develop a mortality prediction model in this population. Materials and methods: Retrospective review of children and adolescents who received a HSCT between January 1st, 2005 and December 31st, 2019 and were admitted to the PICU of a tertiary care teaching hospital. Results: Out of 264 children receiving the transplant 114 were admitted to the PICU. The overall mortality rate was 29 % (n = 34). The type of transplant, underlying disease, febrile neutropenia event, cytomegalovirus infection, respiratory failure, graft versus host disease (GVHD), myeloablative chemotherapy, and previous malnutrition were associated with higher mortality rates. In the multivariate analysis, GVHD (odds ratio [OR]: 2.23; 95 % confidence interval [CI]: 1.92-2.98), need for mechanical ventilation (OR: 2.47; 95 % CI: 1.39-5.73), alternative donor transplant (OR: 1.58; 95 % CI: 1.14-2.17), and previous malnutrition (OR: 1.78; 95 % CI: 1.22-3.89) were associated with a higher mortality rate. Conclusion: In the studied population, 2 out of 3 children who received a HSCT and were admitted to the PICU survived. GVHD, mechanical ventilation, alternative donor transplant, and previous malnutrition were predictors of mortality

Children admitted to a pediatric intensive care unit after hematopoietic stem cell transplantation: Analysis of survival and predictors of mortality. / Niños con trasplante de progenitores hematopoyéticos admitidos en una unidad de cuidados intensivos: análisis de la sobrevida y los factores predictivos de mortalidad.

INTRODUCTION: Hematopoietic stem cell transplantation (HSCT) in children is a procedure that is not exempt of severe complications. Admission to the pediatric intensive care unit (PICU) is associated with a high mortality rate. Objectives: To analyze survival and predictors of mortality among children who received a HSCT and were admitted to the PICU, and to develop a mortality prediction model in this population. MATERIALS AND METHODS: Retrospective review of children and adolescents who received a HSCT between January 1st, 2005 and December 31st, 2019 and were admitted to the PICU of a tertiary care teaching hospital. RESULTS: Out of 264 children receiving the transplant, 114 were admitted to the PICU. The overall mortality rate was 29% (n = 34). The type of transplant, underlying disease, febrile neutropenia event, cytomegalovirus infection, respiratory failure, graft versus host disease (GVHD), myeloablative chemotherapy, and previous malnutrition were associated with higher mortality rates. In the multivariate analysis, GVHD (odds ratio [OR]: 2.23; 95% confidence interval [CI]: 1.92-2.98), need for mechanical ventilation (OR: 2.47; 95% CI: 1.39- 5.73), alternative donor transplant (OR: 1.58; 95% CI: 1.14-2.17), and previous malnutrition (OR: 1.78; 95% CI: 1.22-3.89) were associated with a higher mortality rate. CONCLUSION: In the studied population, 2 out of 3 children who received a HSCT and were admitted to the PICU survived. GVHD, mechanical ventilation, alternative donor transplant, and previous malnutrition were predictors of mortality.

Introducción: El trasplante de células progenitoras hematopoyéticas (TPH) en niños es un procedimiento no exento de complicaciones graves. El ingreso de esta población a unidades de cuidados intensivos pediátricos (UCIP) se asocia con elevada mortalidad. Objetivos: Analizar la sobrevida y los factores predictivos de la mortalidad en niños que recibieron TPH e ingresaron a la UCIP y elaborar un modelo predictivo de mortalidad en esta población. Materiales y métodos: Revisión retrospectiva de niños y adolescentes que recibieron un TPH entre el 01/01/2005 y el 31/12/2019 e ingresaron a la UCIP de un hospital universitario de alta complejidad. Resultados: De un total de 264 niños que recibieron el trasplante, 114 ingresaron a la UCIP. La mortalidad general fue del 29% (n = 34). El tipo de trasplante, enfermedad basal, evento de neutropenia febril, infección por citomegalovirus, insuficiencia respiratoria, enfermedad de injerto contra huésped (EICH), quimioterapia mieloablativa y desnutrición previa se asociaron con tasas de mortalidad más elevadas. En el análisis multivariado, la EICH (razón de posibilidades [OR, por su sigla en inglés]: 2,23; intervalo de confianza del 95% [IC 95%]: 1,92-2,98), la necesidad de ventilación mecánica invasiva (OR: 2,47; IC95%: 1,39-5,73), el trasplante de donante alternativo (OR: 1,58; IC 95%: 1,14-2,17) y la desnutrición previa (OR: 1,78; IC 95%: 1,223-3,89) se asociaron con mayor mortalidad. Conclusión: En la población estudiada, dos de cada tres niños que recibieron TPH e ingresaron a la UCIP sobrevivieron. La EICH, ventilación mecánica, trasplante de donante alternativo y desnutrición previa fueron factores predictivos de mortalidad.

Hypotonic and isotonic intravenous maintenance fluids in hospitalised paediatric patients: a randomised controlled trial.

OBJECTIVE: To compare the changes in serum sodium and acid/base status in patients receiving hypotonic and isotonic solutions. DESIGN: A randomised, controlled and double-blind clinical trial. SETTING: Department of Paediatrics in a tertiary general hospital (Hospital Universitario Austral) in Buenos Aires, Argentina. PATIENTS: Children between 29 days and 15 years of age who were hospitalised in the paediatric intensive care unit and general hospital between 12 January 2010 and 30 November 2016, and who required exclusively parenteral maintenance solutions for at least 24 hours. INTERVENTIONS: A hypotonic solution with 77 mEq/L sodium chloride (0.45% in 5% dextrose) and isotonic solution with 150 mEq/L (0.9% in 5% dextrose) were infused for 48 hours and were labelled. MAIN OUTCOME MEASURE: The main outcome was to evaluate the incidence of hyponatraemia between patients treated with parenteral hydration with hypotonic or isotonic fluids. The secondary outcome was to estimate the incidence of metabolic acidosis induced by each of the solutions. RESULTS: The 299 patients in the present study were randomised to groups that received the hypotonic solution (n=154) or isotonic solution (n=145). The mean serum sodium concentration measurements at 12 hours were 136.3±3.9 mEq/L and 140.1±2.3 mEq/L in the hypotonic and isotonic groups, respectively, with a hyponatraemia incidence of 8.27% (n=12) and 18.8% (n=29) (p<0.001). At 24 hours, 12.4% (n=18) of the isotonic group had developed hyponatraemia compared with 46.1% (n=71) of the hypotonic group (p<0.001). The mean serum sodium concentration measurements were 134.4±5.6 and 139.3±3.1, respectively. No patient developed hypernatraemia (serum sodium concentrations >150 mEq/L) or other adverse outcomes. The relative risk in the hypotonic group was 3.7 (95% CI 2.3 to 5.9), almost four times the risk of developing hyponatraemia than those who received isotonic fluids. There were also no significant differences between the groups with regard to the development of metabolic acidosis. Hypotonic solution, age <12 months and postoperative abdominal surgery were risk factors associated with hyponatraemia. CONCLUSIONS: The incidence of iatrogenic hyponatraemia was greater with the administration of hypotonic fluids compared with that of isotonic fluids. There were no significant differences in the incidence of metabolic acidosis between the groups.

Medición de la incidencia de eventos adversos atribuidos a la atención sanitaria en un Departamento de Pediatría de un hospital universitario / Measurement of the incidence of care-associated adverse events at the Department of Pediatrics of a teaching hospital

Introducción. Los eventos adversos pueden ser detectados por diversas herramientas de pesquisa. En la población pediátrica, la Pediatric Global Trigger Tool busca gatillos en la historia clínica para detectar daño asociado al cuidado, tanto prevenible como no prevenible. Objetivo. Medir la incidencia de eventos adversos en el Departamento de Pediatría utilizando dicha herramienta. Conocer los tipos de eventos y las variables asociadas. Población y métodos. Estudio de incidencia, de corte longitudinal. Resultados. Se estudiaron 318 pacientes; media de edad: 2,99 años (rango: 0-17); porcentaje de mujeres: 164 (el 51,57 %). Se halló un 11 % de eventos por cada 100 admisiones, 15,5 eventos cada 1000 días-paciente. Los eventos más frecuentes fueron asociados a medicación: el 48,57 % (n = 17); a bacteriología (infecciones): el 42,85 % (n = 15); y a cuidados: el 8,57 % (n = 3). Diecinueve eventos fueron leves (el 54,28 %), 14 (el 40 %) prolongaron la hospitalización (moderados) y 2 (el 5,71 %) requirieron soporte vital (graves). Se hallaron 168 gatillos, 0,53 gatillos por paciente, 74,4 gatillos cada 1000 días-paciente y 4,8 gatillos por cada evento adverso. En el análisis de regresión logística multivariada, las variables asociadas a la aparición de los eventos adversos fueron medicamentos de alto riesgo, sexo femenino, peso, número de transferencias dentro del hospital y estancia superior a 5 días. Conclusiones. La utilización de la Pediatric Global Trigger Tool permite identificar eventos adversos en pacientes pediátricos hospitalizados y ayudar a encauzar acciones de mejora, de acuerdo con las variables asociadas.

Introduction. Adverse events may be detected using different screening tools. In the pediatric population, the Pediatric Trigger Tool looks for triggers in the medical record to detect preventable and non-preventable care-associated harm. Objective. To measure the incidence of adverse events at the Department of Pediatrics using this tool. To know the types of events and associated outcome measures. Population and methods. Longitudinal cohort study. Results. A total of 318 patients were included; mean age: 2.99 years (range: 0-17); 164 (51.57 %) were girls. There were 11 % of events per 100 admissions, 15.5 events per 1000patient-days. The most common events were associated with medication use: 48.57 % (n = 17); bacteriology (infections): 42.85 % (n = 15); and care: 8.57 % (n = 3). Nineteen events were mild (54.28 %), 14 (40 %) extended the length of stay (moderate), and 2 (5.71 %) required vital support (severe). A total of 168 triggers were detected; 0.53 triggers per patient, 74.4 triggers per 1000 patient-days, and 4.8 triggers per adverse event. In the multivariate logistic regression analysis, the outcome measures associated with the development of adverse events were high-risk medications, female sex, weight, number of transfers within the hospital, and length of stay longer than 5 days. Conclusions. Using the Pediatric Trigger Tool helped to identify adverse events in hospitalized pediatric patients and guide improvement measures based on associated outcome measures.

Measurement of the incidence of care-associated adverse events at the Department of Pediatrics of a teaching hospital. / Medición de la incidencia de eventos adversos atribuidos a la atención sanitaria en un Departamento de Pediatría de un hospital universitario.

INTRODUCTION: Adverse events may be detected using different screening tools. In the pediatric population, the Pediatric Trigger Tool looks for triggers in the medical record to detect preventable and non-preventable care-associated harm. OBJECTIVE: To measure the incidence of adverse events at the Department of Pediatrics using this tool. To know the types of events and associated outcome measures. POPULATION AND METHODS: Longitudinal cohort study. RESULTS: A total of 318 patients were included; mean age: 2.99 years (range: 0-17); 164 (51.57 %) were girls. There were 11 % of events per 100 admissions, 15.5 events per 1000patient-days. The most common events were associated with medication use: 48.57 % (n = 17); bacteriology (infections): 42.85 % (n = 15); and care: 8.57 % (n = 3). Nineteen events were mild (54.28 %), 14 (40 %) extended the length of stay (moderate), and 2 (5.71 %) required vital support (severe). A total of 168 triggers were detected; 0.53 triggers per patient, 74.4 triggers per 1000 patient-days, and 4.8 triggers per adverse event. In the multivariate logistic regression analysis, the outcome measures associated with the development of adverse events were high-risk medications, female sex, weight, number of transfers within the hospital, and length of stay longer than 5 days. CONCLUSIONS: Using the Pediatric Trigger Tool helped to identify adverse events in hospitalized pediatric patients and guide improvement measures based on associated outcome measures.

Introducción. Los eventos adversos pueden ser detectados por diversas herramientas de pesquisa. En la población pediátrica, la Pediatric Global Trigger Tool busca gatillos en la historia clínica para detectar daño asociado al cuidado, tanto prevenible como no prevenible. Objetivo. Medir la incidencia de eventos adversos en el Departamento de Pediatría utilizando dicha herramienta. Conocer los tipos de eventos y las variables asociadas. Población y métodos. Estudio de incidencia, de corte longitudinal. Resultados. Se estudiaron 318 pacientes; media de edad: 2,99 años (rango: 0-17); porcentaje de mujeres: 164 (el 51,57 %). Se halló un 11 % de eventos por cada 100 admisiones, 15,5 eventos cada 1000 días-paciente. Los eventos más frecuentes fueron asociados a medicación: el 48,57 % (n = 17); a bacteriología (infecciones): el 42,85 % (n = 15); y a cuidados: el 8,57 % (n = 3). Diecinueve eventos fueron leves (el 54,28 %), 14 (el 40 %) prolongaron la hospitalización (moderados) y 2 (el 5,71 %) requirieron soporte vital (graves). Se hallaron 168 gatillos, 0,53 gatillos por paciente, 74,4 gatillos cada 1000 días-paciente y 4,8 gatillos por cada evento adverso. En el análisis de regresión logística multivariada, las variables asociadas a la aparición de los eventos adversos fueron medicamentos de alto riesgo, sexo femenino, peso, número de transferencias dentro del hospital y estancia superior a 5 días. Conclusiones. La utilización de la Pediatric Global Trigger Tool permite identificar eventos adversos en pacientes pediátricos hospitalizados y ayudar a encauzar acciones de mejora, de acuerdo con las variables asociadas.

Performance of the Pediatric Index of Mortality 3 Score in PICUs in Argentina: A Prospective, National Multicenter Study.

OBJECTIVE: To assess the performance of the Pediatric Index of Mortality 3 score in a population of children admitted to PICUs in Argentina. DESIGN: Prospective, national, multicenter study. SETTING: Forty-nine PICUs located in Argentina belonging to public and private institutions. PATIENTS: All children between 1 month and 16 years old admitted to the participating PICUs between May 15, 2016, and February 15, 2017. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: A total of 6,602 patients were enrolled in the study. The observed mortality was 8% (531/6,602), whereas mortality predicted by Pediatric Index of Mortality 3 was 6.16% (407 deaths). The standardized mortality rate was 1.3 (95% CI, 1.20-1.42). The area under the receiver operating characteristic curve was 0.83 (95% CI, 0.82-0.85). The Hosmer-Lemeshow test showed that the difference between the mortality observed and the mortality predicted by Pediatric Index of Mortality 3 was statistically significant (χ, 135.63; p < 0.001). CONCLUSIONS: The Pediatric Index of Mortality 3 score adequately discriminated patients who died from those who survived in our population. However, the observed mortality was higher than predicted by the score. The use of an updated instrument such as Pediatric Index of Mortality 3 will allow an actual comparison between pediatric intensive care provided in the country and care provided internationally. This might also allow future planning of pediatric intensive care services in Argentina.

Reducción de prescripción inapropiada y eventos adversos a medicamentos en ancianos hospitalizados / Reduction of inappropriate prescriptions and adverse effects to medications in hospitalized elderly patients

La combinación de prescripción inapropiada de medicamentos (PIM) y prescripción apropiada omitida (PPO) en ancianos requiere intervenciones múltiples para reducir su magnitud y los subsecuentes eventos adversos. Este estudio tiene como objetivo evaluar la PIM, la PPO, y los eventos adversos a medicamentos (EAM) antes y después de la intervención de un farmacéutico clínico sobre la prescripción del médico. En un estudio de tipo pre-post, se analizó la prescripción de un total de 16 542 fármacos realizada a 1262 pacientes aplicando los criterios STOPP-START (screening tool of older people's prescriptions/screening tool to alert to right treatment). La intervención consistió en la difusión de los criterios STOPP-START en todas las áreas del hospital mediante clases y publicaciones y las sugerencias diarias del farmacéutico clínico al médico responsable sobre la prescripción a cada paciente. Antes de la intervención, la PIM fue 48.9% al ingreso y 46.1% al egreso y luego de la intervención 47.4% al ingreso y 16.7% al egreso. La PPO antes de la intervención fue 10% al ingreso y 7.6% al egreso; después de la intervención fue 12.2% al ingreso y 7.8% al egreso. El porcentaje de pacientes con EAM fue 50.9% antes de la intervención y 34.4% después. Las readmisiones a emergencias fueron 12.2% y 4.7% antes y después de la intervención. La PIM, los EAM, el error de conciliación, la interacción medicamentosa clínicamente grave y el delirio fueron reducidos significativamente. Se concluye que, coincidiendo con buena parte de la literatura internacional, la intervención obtuvo resultados positivos.

Together, potentially inappropriate prescribing of medications (PIP) and appropriate prescribing omission (APO) constitute a problem that requires multiple interventions to reduce its size and the occurrence of adverse drug events (ADE). This study aims to assess PIP, APO, ADE before and after the intervention of a clinical pharmacist over medical prescriptions for elderly hospitalized patients. In a before-after study, a total of 16 542 prescriptions for 1262 patients were analyzed applying the criteria defined in both STOPP- START (screening tool of older people's prescriptions and screening tool to alert to right treatment). The intervention consisted in lectures and publications on STOPP-START criteria made available to all the areas of the hospital and suggestions made by the clinical pharmacist to the physician on each individual prescription. Before intervention, PIM was 48.9% on admission and 46.1% at discharge, while after the intervention it was 47.4% on admission and 16.7% at discharge. APO was 10% on admission and 7.6% at discharge, while after intervention it was 12.2% on admission and 7.9% at discharge. ADE were 50.9% before and 34.4% after intervention. The frequency of return to emergency was 12.2% and 4.7% before and after intervention. PIM, EAM, conciliation error, clinically serious drug interaction, and delirium were reduced to statistically significant levels. In line with various international studies, the intervention showed to attain positive results.

[Reduction of inappropriate prescriptions and adverse effects to medications in hospitalized elderly patients]. / Reducción de prescripción inapropiada y eventos adversos a medicamentos en ancianos hospitalizados.

Together, potentially inappropriate prescribing of medications (PIP) and appropriate prescribing omission (APO) constitute a problem that requires multiple interventions to reduce its size and the occurrence of adverse drug events (ADE). This study aims to assess PIP, APO, ADE before and after the intervention of a clinical pharmacist over medical prescriptions for elderly hospitalized patients. In a before-after study, a total of 16 542 prescriptions for 1262 patients were analyzed applying the criteria defined in both STOPP- START (screening tool of older people's prescriptions and screening tool to alert to right treatment). The intervention consisted in lectures and publications on STOPP-START criteria made available to all the areas of the hospital and suggestions made by the clinical pharmacist to the physician on each individual prescription. Before intervention, PIM was 48.9% on admission and 46.1% at discharge, while after the intervention it was 47.4% on admission and 16.7% at discharge. APO was 10% on admission and 7.6% at discharge, while after intervention it was 12.2% on admission and 7.9% at discharge. ADE were 50.9% before and 34.4% after intervention. The frequency of return to emergency was 12.2% and 4.7% before and after intervention. PIM, EAM, conciliation error, clinically serious drug interaction, and delirium were reduced to statistically significant levels. In line with various international studies, the intervention showed to attain positive results.

American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock.

OBJECTIVES: The American College of Critical Care Medicine provided 2002 and 2007 guidelines for hemodynamic support of newborn and pediatric septic shock. Provide the 2014 update of the 2007 American College of Critical Care Medicine "Clinical Guidelines for Hemodynamic Support of Neonates and Children with Septic Shock." DESIGN: Society of Critical Care Medicine members were identified from general solicitation at Society of Critical Care Medicine Educational and Scientific Symposia (2006-2014). The PubMed/Medline/Embase literature (2006-14) was searched by the Society of Critical Care Medicine librarian using the keywords: sepsis, septicemia, septic shock, endotoxemia, persistent pulmonary hypertension, nitric oxide, extracorporeal membrane oxygenation, and American College of Critical Care Medicine guidelines in the newborn and pediatric age groups. MEASUREMENTS AND MAIN RESULTS: The 2002 and 2007 guidelines were widely disseminated, translated into Spanish and Portuguese, and incorporated into Society of Critical Care Medicine and American Heart Association/Pediatric Advanced Life Support sanctioned recommendations. The review of new literature highlights two tertiary pediatric centers that implemented quality improvement initiatives to improve early septic shock recognition and first-hour compliance to these guidelines. Improved compliance reduced hospital mortality from 4% to 2%. Analysis of Global Sepsis Initiative data in resource rich developed and developing nations further showed improved hospital mortality with compliance to first-hour and stabilization guideline recommendations. CONCLUSIONS: The major new recommendation in the 2014 update is consideration of institution-specific use of 1) a "recognition bundle" containing a trigger tool for rapid identification of patients with septic shock, 2) a "resuscitation and stabilization bundle" to help adherence to best practice principles, and 3) a "performance bundle" to identify and overcome perceived barriers to the pursuit of best practice principles.

[Inappropriate prescription in elderly inpatients]. / Prescripción inapropiada en adultos mayores hospitalizados.

One of the causes of preventable adverse drug events (EAM) in the older adult population is the inappropriate prescription (PIM), i.e. that prescription where risks outweigh clinical benefits. The aim of this study is to determine the incidence of PIM with Beers criteria and Screening Tool of older person's prescriptions (STOPP), Potentially Prescribing Omissions (PPO) with Screening Tool to alert doctors to Right Treatments (START), and the average costs of hospitalization. This is an incidence study on a sample of patients over 64 years hospitalized, from January to July 2014 at a university hospital. According to Beers criteria, PIM incidence was 61.4%, 65.4% with STOPP and 27.6% PPO with START. The EAM rate calculated was 15.2/100 admissions and 18.6 EAM / 1000 patient days. The OR of EAM with PIM according to Beers and STOPP was 1.49 (IC95% 1.68-4.66) and 1.17 (IC95% 0.62-2.24) respectively. The average cost of hospitalization in patients with EAM were higher than without EAM (p = 0.020). PIM results are in line with most of the studies cited, but slightly higher for Beers and STOPP and lower for START, and the rate of EAM is lower than the data found by Kanaan (18.7% vs. 15.2%). PIM contributes to the appearance of EAM. The costs of hospitalizations with EAM are higher than those without EAM, achieving level of significance.

Prescripción inapropiada en adultos mayores hospitalizados / Inappropriate prescription in elderly inpatients

Una de las causas prevenibles de los eventos adversos a medicamentos (EAM) en la población adulta mayor es la prescripción inapropiada, (PIM), es decir aquella prescripción donde los riesgos superan los beneficios clínicos. Se propone conocer la incidencia de PIM con los criterios de Beers, los Screening tool of older person´s prescriptions (STOPP), la omisión de prescripción apropiada (PPO) con Screening tool to alert doctors to right treatment (START) y los costos medios de hospitalización. Es un estudio de incidencia de una muestra de pacientes > 64 años, internados en el periodo enero-julio 2014 en un hospital universitario. Se halló una incidencia de PIM de 61.4% con los criterios de Beers, 65.4% con STOPP y 27.6% de PPO con START. Se calculó una tasa de EAM de 15.2 EAM/100 admisiones y 18.6 EAM/1000 días paciente. El OR de EAM con PIM según Beers y STOPP fue 1.49 (IC95% 1.68-4.66) y 1.17 (IC95% 0.62-2.24) respectivamente. El costo de hospitalización en pacientes con EAM fue mayor que sin EAM (p = 0.020). Los resultados de PIM son similares a la mayoría de los estudios publicados, aunque levemente mayores para Beers y STOPP y menores para START. La tasa de EAM es inferior a la encontrada por Kanaan (18.7% vs. 15.2%). Hay una contribución de PIM a la aparición de EAM.

One of the causes of preventable adverse drug events (EAM) in the older adult population is the inappropriate prescription (PIM), i.e. that prescription where risks outweigh clinical benefits. The aim of this study is to determine the incidence of PIM with Beers criteria and Screening Tool of older person´s prescriptions (STOPP), Potentially Prescribing Omissions (PPO) with Screening Tool to alert doctors to Right Treatments (START), and the average costs of hospitalization. This is an incidence study on a sample of patients over 64 years hospitalized, from January to July 2014 at a university hospital. According to Beers criteria, PIM incidence was 61.4%, 65.4% with STOPP and 27.6% PPO with START. The EAM rate calculated was 15.2/100 admissions and 18.6 EAM / 1000 patient days. The OR of EAM with PIM according to Beers and STOPP was 1.49 (IC95% 1.68-4.66) and 1.17 (IC95% 0.62-2.24) respectively. The average cost of hospitalization in patients with EAM were higher than without EAM (p = 0.020). PIM results are in line with most of the studies cited, but slightly higher for Beers and STOPP and lower for START, and the rate of EAM is lower than the data found by Kanaan (18.7% vs. 15.2%). PIM contributes to the appearance of EAM. The costs of hospitalizations with EAM are higher than those without EAM, achieving level of significance.

Pediatric Index of Mortality 2 as a predictor of death risk in children admitted to pediatric intensive care units in Latin America: A prospective, multicenter study.

PURPOSE: The purpose of this study is to asses the performance of the Pediatric Index of Mortality 2 (PIM2) score in pediatric intensive care units (PICUs) in Latin America. MATERIALS AND METHODS: This is a prospective, observational, multicenter study. We included patients aged 1 month to 16 years old admitted consecutively during 1 year to 34 PICUs in 9 Latin American countries. Discrimination and calibration tests were performed to validate the performance of PIM2 in the entire sample and in different subgroups. RESULTS: A total of 7391 patients were analyzed. Pediatric Index of Mortality 2 predicted 573 deaths, whereas the observed deaths were 663 (P < .001). The area under the receiver operating characteristic curve for the entire population was 0.817 (95% confidence interval, 0.808-0.825). The score showed good discrimination. Instead, calibration was inadequate. The difference between observed and predicted deaths for the entire population and across different risk intervals was statistically significant (χ(2) = 121.87; df = 8; P < .001). Pediatric Index of Mortality 2 did not predict mortality correctly in different diagnostic categories (injury, postoperative, and miscellaneous), in children younger than 12 months, adolescents, and patients with chronic complex conditions. CONCLUSIONS: Pediatric Index of Mortality 2 showed good discrimination, but calibration was inadequate. To use PIM2 for monitoring PICU performance in Latin America, it might be necessary to recalibrate the score locally.

Validación del índice pediátrico de mortalidad 2 (PIM2) en Argentina: un estudio prospectivo, multicéntrico, observacional / Validation of the Pediatric Index of Mortality 2 (PIM2) in Argentina: a prospective, multicenter, observational study

Introducción. El índice pediátrico de mortalidad 2 (Pediatric Index of Mortality 2; PIM2, por sus siglas en inglés) es uno de los puntajes más utilizados para la predicción de la mortalidad en pacientes ingresados en las Unidades de Cuidados Intensivos Pediátricos (UCIP) argentinas. El objetivo de este estudio fue validar el puntaje PIM2 en las UCIP integrantes del Programa de Calidad de Atención de la Sociedad Argentina de Terapia Intensiva. Población y métodos. Estudio multicéntrico, prospectivo, observacional, de corte transversal. Se incluyeron todos los pacientes de entre 1 mes y 16 años de edad, ingresados en las UCIP participantes entre el 01-01-2009 y el 31-122009. Se evaluó la discriminación y calibración del puntaje PIM2 en toda la población y en diferentes subgrupos (riesgo de mortalidad, edad, diagnósticos de ingreso). Resultados. Se incluyeron 2832 pacientes. El PIM2 predijo 246 muertes; sin embargo, fallecieron 297 pacientes (p <0,01). La razón de mortalidad estandarizada fue 1,20 (IC 95%: 1,01-1,43). El área bajo la curva ROC fue 0,84 (IC 95%: 0,82-0,86). Se detectaron diferencias estadísticamente significativas entre las muertes observadas y las predichas para toda la población y en los distintos intervalos de riesgo (χ² 71,02; df 8; p <0,001). También se detectaron diferencias estadísticamente significativas entre las muertes observadas y esperadas en los pacientes adolescentes (37/22, p= 0,03) y en aquellos ingresados con patología respiratoria (105/81, p= 0,03). Conclusiones. El puntaje PIM2 permite diferenciar adecuadamente los pacientes que sobreviven de aquellos que fallecen. Sin embargo, subvalora el riesgo de muerte en forma global, especialmente en los pacientes adolescentes y en aquellos ingresados por causa respiratoria. Es fundamental considerar estas diferencias al interpretar los resultados.

Introduction. The Pediatric Index of Mortality 2 (PIM2) is one of the most commonly used scoring systems to predict mortality in patients admitted to pediatric intensive care units (PICU) in Argentina. The objective of this study was to validate the PIM2 score in PICUs participating in the Quality of Care Program promoted by the Argentine Society of Intensive Care.Population and Methods. Multicenter, prospective, observational, cross-sectional study.All patients between 1 month and 16 years old admitted to participating PICUs between January 1st, 2009 and December 31st, 2009 were included. The discrimination and calibration of the PIM2 score were assessed in the entire population and in different subgroups (risk of mortality, age, diagnoses on admission).Results. Two thousand, eight hundred and thirty-two patients were included. PIM2 predicted 246 deaths; however, 297 patients died (p < 0.01). The standardized mortality ratio was 1.20 (95% confidence interval [CI]: 1.01-1.43). The area under the ROC curve was 0.84 (95% CI: 0.82-0.86). Statistically significant differences were detected between the observed and the predicted mortality for the entire population and for the different risk intervals (χ²: 71.02, df: 8, p < 0.001). Statistically significant differences were also found between observed and predicted mortality in adolescent patients (37/22, p = 0.03) and in those hospitalized due to respiratory disease (105/81, p = 0.03).Conclusions. The PIM2 score adequately discriminates survivors from non-survivors. However, it underscores the overall risk of death, especially in adolescent patients and those hospitalized due to respiratory disease. It is critical to take such differences into account when interpreting results.

Validation of the Pediatric Index of Mortality 2 (PIM2) in Argentina: a prospective, multicenter, observational study.

INTRODUCTION: The Pediatric Index of Mortality 2 (PIM2) is one of the most commonly used scoring systems to predict mortality in patients admitted to pediatric intensive care units (PICU) in Argentina. The objective of this study was to validate the PIM2 score in PICUs participating in the Quality of Care Program promoted by the Argentine Society of Intensive Care. POPULATION AND METHODS: Multicenter, prospective, observational, cross-sectional study. All patients between 1 month and 16 years old admitted to participating PICUs between January 1st, 2009 and December 31st, 2009 were included. The discrimination and calibration of the PIM2 score were assessed in the entire population and in different subgroups (risk of mortality, age, diagnoses on admission). RESULTS: Two thousand, eight hundred and thirty-two patients were included. PIM2 predicted 246 deaths; however, 297 patients died (p < 0.01). The standardized mortality ratio was 1.20 (95% confidence interval [CI]: 1.01-1.43). The area under the ROC curve was 0.84 (95% CI: 0.82-0.86). Statistically significant differences were detected between the observed and the predicted mortality for the entire population and for the different risk intervals (χ2: 71.02, df: 8, p < 0.001). Statistically significant differences were also found between observed and predicted mortality in adolescent patients (37/22, p = 0.03) and in those hospitalized due to respiratory disease (105/81, p = 0.03). CONCLUSIONS: The PIM2 score adequately discriminates survivors from non-survivors. However, it underscores the overall risk of death, especially in adolescent patients and those hospitalized due to respiratory disease. It is critical to take such differences into account when interpreting results.

Effectiveness of magnesium sulfate as initial treatment of acute severe asthma in children, conducted in a tertiary-level university hospital: a randomized, controlled trial.

INTRODUCTION: Magnesium sulfate is a calcium antagonist that inhibits bronchial smooth muscle contraction promoting bronchodilation. It is used for the management of acute severe asthma in children; however most of the studies have been performed in adults. OBJECTIVE: To evaluate the effectiveness of intravenous magnesium sulfate for the treatment of pediatric patients with acute severe asthma exacerbations. POPULATION AND METHODS: A clinical, randomized, controlled trial was conducted between March 2006 and March 2011 at Hospital Universitario Austral. Children with acute severe asthma admitted to the emergency department were randomized into two groups. Group A (control group): standard protocol for the initial treatment of acute asthma exacerbation. Group B: treatment protocol with magnesium sulphate for acute severe asthma exacerbation. The primary outcome was the requirement of invasive or non invasive mechanical ventilation support. RESULTS: One hundred and forty three patients randomized into 2 groups were analyzed. The treatment group included 76 patients receiving magnesium sulfate within the first hour of the initiation of rescue treatment at the hospital, and the control group included 67 patients not treated with magnesium sulphate. Among the patients in the control group, 33% (n= 22) required mechanical ventilation support, compared to only 5% (n= 4) of the patients in the treatment group (p = 0.001). CONCLUSIONS: Intravenous infusion of magnesium sulfate during the first hour of hospitalization in patients with acute severe asthma significantly reduced the percentage of children who required mechanical ventilation support.

Effectiveness of magnesium sulfate as initial treatment of acute severe asthma in children, conducted in a tertiary-level university hospital: A randomized, controlled trial / Eficacia del sulfato de magnesio como tratamiento inicial del asma aguda grave pediátrica: Estudio aleatorizado y controlado

Introduction. Magnesium sulfate is a calcium antagonist that inhibits bronchial smooth muscle contraction promoting bronchodilation. It is used for the management of acute severe asthma in children; however most of the studies have been performed in adults. Objective. To evaluate the effectiveness of intravenous magnesium sulfate for the treatment of pediatric patients with acute severe asthma exacerbations. Population and Methods. A clinical, randomized, controlled trial was conducted between March 2006 and March 2011 at Hospital Universitario Austral. Children with acute severe asthma admitted to the emergency department were randomized into two groups. Group A (control group): standard protocol for the initial treatment of acute asthma exacerbation. Group B: treatment protocol with magnesium sulphate for acute severe asthma exacerbation. The primary outcome was the requirement of invasive or non invasive mechanical ventilation support. Results. One hundred and forty three patients randomized into 2 groups were analyzed. The treatment group included 76 patients receiving magnesium sulfate within the first hour of the initiation of rescue treatment at the hospital, and the control group included 67 patients not treated with magnesium sulphate. Among the patients in the control group, 33% (n= 22) required mechanical ventilation support, compared to only 5% (n= 4) of the patients in the treatment group (p = 0.001). Conclusions. Intravenous infusion of magnesium sulfate during the first hour of hospitalization in patients with acute severe asthma significantly reduced the percentage of children who required mechanical ventilation support.

Introducción. El sulfato de magnesio es un antagonista del calcio que inhibe la contracción del músculo liso bronquial y favorece la broncodilatación. Se utiliza en el manejo del asma aguda grave en pediatría no obstante haber sido la mayoría de los estudios desarrollados en adultos. Objetivo. Evaluar la eficacia del sulfato de magnesio endovenoso para exacerbaciones graves de pacientes asmáticos pediátricos. Población y métodos. Se realizó un estudio clínico, controlado y aleatorizado, entre marzo de 2006 y marzo de 2011 en el Hospital Universitario Austral. Los pacientes con asma aguda grave admitidos en Emergencias se aleatorizaron en dos grupos. Grupo A: protocolo inicial estándar de exacerbación asmática aguda grave. Grupo B: protocolo de intervención con sulfato de magnesio de exacerbación asmática aguda grave. La variable principal de resultado fue la necesidad de soporte invasivo o no invasivo ventilatorio mecánico. Resultados. Se analizaron 143 pacientes aleatorizados en 2 grupos. El grupo de intervención de 76 pacientes que recibieron tratamiento con sulfato de magnesio dentro de la primera hora de iniciado el tratamiento de rescate en el hospital, y el grupo control testigo de 67 pacientes que no recibieron tratamiento con sulfato de magnesio. El 33% (n= 22) de los pacientes del grupo control requirió asistencia ventilatoria mecánica, en comparación con solo 4 (5%) de los pacientes del grupo intervención (p= 0,001). Conclusiones. El uso de sulfato de magnesio en infusión endovenosa en la primera hora de ingreso del paciente con asma aguda grave redujo significativamente el porcentaje de niños que requirieron asistencia ventilatoria mecánica.